nantkwest.com
Get leads like Nantkwest — and thousands more
Build targeted lists by tech stack, and more
ImmunityBio: The $103M Bet on Cancer Vaccines
Deep dive into nantkwest.com, the biotech disrupting immunotherapy from the ground up
While legacy pharma giants shuffle deck chairs on the Titanic of chemotherapy, ImmunityBio is building a lifeboat. With $103.5M in funding and a laser focus on ANKTIVA®, this isn't just another biotech—it's a calculated strike on cancer's most stubborn defenses.
"They aren't just treating cancer—they're reprogramming the immune system to hunt it down like a predator."
The ANKTIVA® Arsenal
ImmunityBio's crown jewel is ANKTIVA®, a first-in-class IL-15 agonist that doesn't just attack tumors—it educates the immune system to remember them. While competitors focus on checkpoint inhibitors, ImmunityBio is building a multi-pronged assault: cell therapies, cancer vaccines, and cytokine platforms. The Saudi FDA's accelerated approval for NSCLC and NMIBC CIS isn't just regulatory paperwork—it's validation of a platform that could redefine immunotherapy standards.
The Growth Paradox
Here's the fascinating contradiction: 61 employees generating $4.7M in revenue yet commanding $103.5M in funding. This isn't a burn-rate problem—it's a strategic concentration. They're not spreading resources thin across 20 programs; they're deepening the moat around ANKTIVA®. The 700% net product revenue growth suggests they've found the rare intersection of clinical efficacy and commercial viability. For investors, this is the sweet spot: pre-revenue risk has passed, but scaling potential remains exponential.
The leadership team tells the story of execution. CEO Richard Adcock brings operational discipline to a field often paralyzed by academic idealism. Hans Klingemann (VP R&D) and Leonard Sender (SVP Medical Affairs) represent the scientific backbone, while Steve Danso and Daniel Laureano handle the logistics nightmare that is biotech supply chains. This isn't a lab curiosity—it's a company built to scale.
- Multi-modal platform: Cell therapy + cancer vaccines + cytokines
- Regulatory momentum: Saudi FDA accelerated approvals
- Clinical validation: VA Medical Center trials for bladder cancer
- Commercial traction: 700% revenue growth signals market readiness
The Verdict: A High-Conviction Bet
ImmunityBio isn't betting on cancer treatment—it's betting on cancer prevention. With ANKTIVA® already generating revenue and regulatory wins stacking up, this is one of the few biotechs where the science and business model align. For founders, it's a masterclass in focused execution. For investors, it's a rare combination of de-risked clinical data and massive upside. The question isn't whether they'll succeed—it's whether the market will recognize the value before the data becomes undeniable.
What tech stack does Nantkwest use?
How much traffic does Nantkwest get?
Traffic & Engagement
How is Nantkwest's SEO?
Open Graph Image
https://immunitybio.com/wp-content/uploads/2025/09/paging-arrow-white.svg
Meta Tags
Immunotherapy by ImmunityBio - Cancer Vaccine Research
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
H1 Tags
Schema Types
What is Nantkwest's revenue?
Who works at Nantkwest?
Loading leads...
What do customers think of Nantkwest?
No Trustpilot reviews available for this company.
Frequently Asked Questions about Nantkwest
What is Nantkwest's Revenue?
What does Nantkwest do?
How fast is Nantkwest growing?
What technologies does Nantkwest use?
Who are Nantkwest's competitors?
Export Data
Unlock all exports
Download CSVs, JSONs & full reports
How to contact Nantkwest?
Contact Information
Export nantkwest.com Data
Download the complete tech stack, analytics, leads, and company data for nantkwest.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.
Raw JSON Data
Click "Show" to view the raw API response data
About nantkwest.com
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
Company Overview
nantkwest.com Social Media
Contact nantkwest.com
Email Addresses
Phone Numbers
Technology Stack
nantkwest.com uses 26 technologies across their website including AccessiBe, Font Awesome, Adobe Fonts, HSTS, and more.
Accessibility
AccessiBe
Fonts
Font Awesome, Adobe Fonts, Google Fonts
Security
HSTS
Programming Languages
PHP
CMS
WordPress
CDN
unpkg, jsDelivr
Traffic & Audience
nantkwest.com receives approximately 0 monthly visitors. The website has a bounce rate of 0% with visitors viewing an average of 0.0 pages per visit. Users spend an average of 0:00 on the site.
Frequently Asked Questions
What is nantkwest.com?
What technologies does nantkwest.com use?
How do I contact nantkwest.com?
What are nantkwest.com's social media accounts?
Is nantkwest.com hiring?
How popular is nantkwest.com?
Related Searches
This page provides publicly available information about nantkwest.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit nantkwest.com directly at https://nantkwest.com.